Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Other Non-Current Assets (2019 - 2026)

ADC Therapeutics has reported Other Non-Current Assets over the past 8 years, most recently at $1.2 million for Q1 2026.

  • Quarterly results put Other Non-Current Assets at $1.2 million for Q1 2026, up 7.14% from a year ago — trailing twelve months through Mar 2026 was $1.2 million (up 7.14% YoY), and the annual figure for FY2025 was $1.2 million, up 4.82%.
  • Other Non-Current Assets reached $1.2 million in Q1 2026 per ADCT's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.4 million in Q2 2023 and bottomed at $711000.0 in Q4 2023.
  • Median Other Non-Current Assets over the past 5 years was $1.2 million (2024), compared with a mean of $1.1 million.
  • The largest annual shift saw Other Non-Current Assets surged 130058.73% in 2022 before it tumbled 31.25% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $902000.0 in 2022, then decreased by 21.18% to $711000.0 in 2023, then skyrocketed by 63.29% to $1.2 million in 2024, then grew by 4.82% to $1.2 million in 2025, then increased by 2.38% to $1.2 million in 2026.
  • Business Quant data shows Other Non-Current Assets for ADCT at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.